International Journal of Medicinal Mushrooms

ISSN for PRINT: 1521-9437

For Online Access

Best Paper Award Selection - Editorial Board Site

2002, Volume4

Issue 3

94 pages

Issue price - $128.00

Jacqueline Koch
Institute of Pharmaceutical Biology, Ernst-Moritz-Arndt-University of Greifswald, F.-L.-Jahn-Str. 17a, D-17487 Greifswald, Germany

Sabine Witt
Biometec GmbH, W.-Rathenau-Str. 49a; D-17489 Greifswald, Germany

Ulrike Lindequist
Institute of Pharmaceutical Biology, Ernst-Moritz-Arndt-University of Greifswald, F.-L.-Jahn-Str. 17a, D-17487 Greifswald, Germany

135 extracts of 22 species of Higher Basidiomycetes were screened for their ability to inhibit binding of FITC-labeled endotoxin (LPS) to CD14+ cells and to influence LPS-induced release of proinflammatory cytokines (IL-1b, IL-6, TNF-a), regulatory cytokines (IL-2, IL-4, IL-10, IFN-g), and the release of reactive oxygen species (ROS). Prescreening studies examined cytotoxic effects and LPS content of the extracts. The dichlormethane, ethanolic, and aqueous extracts of fruiting bodies of the following species were shown to be active in at least one of the test systems: Daedalea quercina, Ganoderma pfeifferi, Heterobasidion annosum, Lacfarius vellereus, Laetiporus sulphurous, Phaeolus schweinizii, Piptoporus betulmus, Pleurotus ostreatus, Polyporus badius, Sparassis crispa, Thelephora terrestris, Trametes versicolor, and Tricholomopsis rutilans. Extracts of the following fungi were not active in the test systems used: A. campestris, Agaricus vaporarius, Ganoderma lipsiense, G. lucidum, Hapalopilus nidulans, Hericium erinaceus, Inonotus obliquus, Kuehneromyces mutabilis, and Meripilus giganteus.

Download article, 7 pages

Article price - $35.00

<< Previous article   Next article >>